类风湿关节炎中停用TNF靶向生物DMARDs的解读
综述探讨RA患者停用TNF靶向bDMARDs的可行性。早期RA约半数患者可在达到低疾病活动或缓解后停药无复发,已建立RA停药后维持缓解者较少,1年成功停药率13%至48%不一。停药时深度缓解是已建立RA维持治疗假期的关键因素。
要点
- 早期RA约半数患者停用TNF靶向bDMARDs后无临床复发和功能损害。
- 已建立RA停药后维持缓解者少于早期RA,1年成功率13%至48%不等。
- 停药时深度缓解是已建立RA维持bDMARDs治疗假期的关键因素。
核心结论
- 早期RA患者在获得低疾病活动或缓解后可考虑停用TNF靶向bDMARDs,约半数可无复发。
- 已建立RA停药后维持缓解的比例较低且研究间结果不一,停药时深度缓解是维持治疗假期的关键因素。
研究设计与样本
- 综述汇总多项关于RA患者停用TNF靶向bDMARDs的研究结果。
主要发现
- 早期RA约半数患者停用TNF靶向bDMARDs后无临床复发和功能损害。
- 已建立RA停药后维持缓解或低疾病活动者少于早期RA,1年成功停药率13%至48%不等。
- 阿达木单抗停药研究和英夫利西单抗诱导缓解研究显示,停药时深度缓解是已建立RA维持bDMARDs治疗假期的关键因素。
关键数值与推荐
- 早期RA在bDMARDs联合MTX获得低疾病活动或缓解后,约半数可停用TNF靶向bDMARDs无复发。
- 已建立RA停用bDMARDs后1年成功停药率为13%至48%。
临床怎么用
- 早期RA达到低疾病活动或缓解后可考虑停用TNF靶向bDMARDs,但需权衡临床、结构和功能结局恶化风险并密切监测。
- 已建立RA停药前应追求深度缓解以增加维持治疗假期的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combined use of MTX and biological DMARDs (bDMARDs) targeting TNF has revolutionized treatment of RA, and clinical remission becomes a realistic treatment goal. After sustained remission, discontinuation of bDMARDs without disease flare has been emerging as an important theme from the risk-benefit point of view and economic burden. According to several studies, approximately half of early RA patients could discontinue TNF-targeted bDMARDs without clinical flare and functional impairment after obtaining low disease activity or remission by treatment with bDMARDs and MTX. For established RA, however, fewer patients sustained remission or low disease activity after the discontinuation of bDMARDs, compared with early RA. The results were controversial among studies, and the percentage of patients who could successfully discontinue bDMARDs ranged from 13 to 48% at 1 year after discontinuation. From the adalimumab discontinuation without functional and radiographic damage progression following sustained remission study and the induction of remission by infliximab in RA study, deep remission at discontinuation was a key factor for maintaining the treatment holiday of bDMARDs in established RA patients. However, such early intensive treatment would have the potential for reducing drug-induced adverse effects and reducing long-term medical costs, although the risks of worsening clinical, structural and functional outcomes should be considered, with careful monitoring.
引用
- Tanaka Y. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology (Oxford). 2016. PMID: 27856656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。